Claims for Patent: 10,881,624

Summary for Patent: 10,881,624

Title:	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	16/129,531
Patent Claims:	1. A method of increasing a dextromethorphan plasma level in a human being, comprising co-administering bupropion with dextromethorphan to the human being twice a day for at least eight consecutive days, wherein a total of about 200 mg per day to about 300 mg per day of bupropion is administered, wherein the human being is an extensive metabolizer of dextromethorphan and in need of treatment with dextromethorphan, wherein the dextromethorphan plasma level on the fifth day of the co-administration twice a day is at least about 10 times the dextromethorphan plasma level that would be achieved by administering the same amount of dextromethorphan twice a day without bupropion, and wherein the co-administration twice a day results in a C.sub.min of dextromethorphan that on the eighth day, is at least about 20 times the C.sub.min that would be achieved by administering the same amount of dextromethorphan twice a day without bupropion for eight consecutive days. 2. The method of claim 1, wherein the dextromethorphan plasma level on the fifth day bupropion is co-administered with dextromethorphan twice a day is at least about 20 times the dextromethorphan plasma level that would be achieved by administering the same amount of dextromethorphan twice a day without bupropion. 3. The method of claim 1, wherein bupropion and dextromethorphan are administered in a single dosage form. 4. The method of claim 3, wherein the single dosage form is a solid. 5. The method of claim 4, wherein about 40 mg to about 70 mg of dextromethorphan is administered in the single dosage form. 6. The method of claim 1, wherein about 80 mg per day to about 140 mg per day of dextromethorphan is administered. 7. The method of claim 1, wherein about 60 mg per day to about 100 mg per day of dextromethorphan is administered. 8. The method of claim 1, wherein about 200 mg per day to about 250 mg per day of bupropion is administered. 9. The method of claim 1, wherein about 250 mg per day to about 300 mg per day of bupropion is administered. 10. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is at least about 400 nghr/m L. 11. The method of claim 1, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is about 700 nghr/mL to about 1000 nghr/mL. 12. The method of claim 1, wherein the C.sub.max of dextromethorphan on the eighth day is about 70 ng/mL to about 100 ng/mL. 13. A method, comprising co-administering a total of about 60 mg per day to about 140 mg per day of dextromethorphan, with a total of about 200 mg per day to about 300 mg per day of bupropion, to a human being in need of treatment with dextromethorphan, wherein dextromethorphan and bupropion are co-administered to the human being twice a day for at least eight consecutive days, wherein the co-administration is effective for converting the human being from an extensive metabolizer of dextromethorphan to a poor metabolizer of dextromethorphan or an intermediate metabolizer of dextromethorphan, and wherein the co-administration twice a day results in an AUC.sub.0-12 of dextromethorphan that on the eighth day, is at least about 20 times the AUC.sub.0-12 that would be achieved by administering the same amount of dextromethorphan twice a day without bupropion for eight consecutive days. 14. The method of claim 13, wherein the co-administration is effective for converting the human being from an extensive metabolizer of dextromethorphan to a poor metabolizer of dextromethorphan. 15. The method of claim 13, wherein about 85 mg per day to about 95 mg per day of dextromethorphan is administered. 16. The method of claim 13, wherein bupropion and dextromethorphan are co-administered in a single, solid oral dosage form. 17. The method of claim 13, wherein the AUC.sub.0-12 of dextromethorphan on the eighth day is between about 700 nghr/mL and about 1000 nghr/mL. 18. The method of claim 13, wherein the C.sub.max of dextromethorphan on the eighth day is at least about 50 ng/mL. 19. The method of claim 13, wherein the C.sub.max of dextromethorphan on the eighth day is at least about 70 ng/mL.